International Partner Search

Research & Development Request

A Spanish center for applied medical research is looking for partners (company, R&D centre, university) with experience in toxicological analyses under GLP (Good Laboratory Practices) conditions for collaborating in an ERA-NET (Euronanomed III) project

Country of Origin: Spain
Reference Number: RDES20210510001
Publication Date: 10 May 2021

Summary

The Spanish center has applied to the Euronanomed 2021 call (ERA-NET) and they have passed the first evaluation stage. For the full proposal, the research group is looking for partners (company, R&D centre, university) with experience in toxicological analyses under GLP (Good Laboratory Practices) conditions to be part of the consortium under a cooperation agreement and continue with the project in which they will test nanoparticles prepared with specific siRNAs to treat the ischemic heart.

Description

A Spanish center for applied medical research needs a partner with experience in toxicological analyses under GLP (Good Laboratory Practices) conditions for preparing the full proposal for the second phase of Euronanomed-2021call (ERA-NET). The first proposal has been submitted on time and has passed the first evaluation stage. Fortunately, they can include new members in the consortium for this second phase project.



The current consortium members are from France, Israel, Poland and Spain with expertise in nanotechnology, cardiology, chemistry and biology, either in basic science or clinic testing. The research teams also come from academia, industry and clinic sector.



In the project, they will test nanoparticles prepared with specific siRNAs to treat the ischemic heart. This is a very novel formulation that they already have tested in vivo in a murine model of myocardial infraction, confirming great retention into the heart and proper release to the cells. The project plan is to test them also in a pig preclinical model of myocardial infarction to determine their potential application in the clinic. Therefore, they would like to perform GLP-toxicological studies in rodents to confirm the safety of the particles.



The project is coordinated by the Spanish research group, which has deep experience in the development and application of advances therapies for the treatment of cardiac diseases. The research group from Israel has an extensive knowledge in the production of delivery systems and has patented the siRNA-nanoparticles formulation that will be tested in the project. The research group from France has extensive preclinical and clinical experience in cardiology. Finally, the Polish research group is a chemical company specialized in the production of RNA molecules.



In the project, the particles will be tested at the preclincial level, so the consortium is looking for a partner (companies, R&D centres, universities...) with expertise in toxicology and with capacity to perform the studies under GLP conditions for the cooperation in the European project under a collaboration agreement. 



Official deadline for the call: 10th June 2021

Deadline for expressions of interest: 21st May 2021

Anticipated duration of the project: 104 weeks

Stage Of Development

Concept stage

Requested partner

- Type of partner sought:

Company, research centre, university.



- Specific area of activity of the partner:

Partner with expertise in toxicological analyses under GLP conditions.



- Task to be performed:

Toxicological studies for novel nanoparticles in vivo (rodent models of toxicology).



- EU / International project experience:

Not mandatory but recommended.